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1040-71 Interhospital Transfers Are Costly, Cause Delays and Do 
Not Address the Imbalance of Access to 
Revascularization: The Case for More Angiographic 
Facilities? Results From the Global Registry of Acute 
Coronary Events
Ameet Bakhai, Omar H. Dabbous, David J. Cohen, Marcus D. Flather, Dan Greenberg, 
Frederick A. Anderson, Jr., Enrique P. Gurfinkel, Kami White, Keith A.A Fox, The GRACE 
Investigators, Royal Brompton Hospital, London, United Kingdom
Background Hospital revascularization rates for patients (pts) admitted with acute coro-
nary syndromes (ACS) vary depending on proximity to a hospital capable of coronary
revascularization. We examined whether interhospital transfers balance out these varia-
tions and represent the most effective use of resources.
Methods We compared clinical outcomes, resource use and costs for ACS pts enrolled
in GRACE to Dec ’02, presenting directly to centers with (Rv+) or without (Rv-) 24h
access to revasc (PCI/CABG) facilities and for pts transferred (Tr) to a Rv+ unit for acute
care. Costs were estimated ($/€) using key drivers: length of stay, ward type and use of
PCI, stent or CABG.
Results 25,344 pts presented initially to Rv+ (74%) and Rv- (26%). Almost 1 in 5 pts
needed acute Tr. Overall hospital mortality rates were similar (5.4%) for Rv+ and Rv- pts.
Mean cost of all ACS pts was $6001/€5253. Almost 1 in 3 Tr pts did not proceed to
revasc. In the UK alone, the estimated cost of care of Tr pts annually would be $50(€42)
million.
Conclusions Tr rates would have to increase from 20% to 60% to balance the substan-
tial differences in revasc rates between centers. Access to angiography before Tr would
realise substantial potential cost savings by avoiding Tr for pts unlikely to proceed to
revasc. Further economic data is urgently needed to determine the most optimal use of
resources. Increased angiographic facilities may also allow more equitable access to
early revasc for all ACS pts with suitable anatomy.
1040-72 Are American College of Cardiology/American Heart 
Association Preoperative Practice Guidelines for Stress 
Testing Followed?
Howard Weinstein, Barbara Spaltro, Richard M. Steingart, Memorial Sloan-Kettering 
Cancer Center, New York, NY
Background: ACC/AHA preoperative practice guidelines for stress testing are widely
promulgated but the extent to which they are followed and applicable in specialized popu-
lations is unknown.
Methods: Accordingly, we retrospectively applied the ACC/AHA preoperative guidelines
to a group of 776 consecutive patients (pts) undergoing abdominal, genitourinary, head
and neck or thoracic cancer surgery referred for preoperative exercise stress echocardio-
graphy (ESE).
Results: Eighty-four percent of stress tests were not indicated by existing ACC/AHA
guidelines. The rate of cardiac events (AMI, CHF, UA and death ) in these pts was low
(1.8%) and ESE provided no further risk stratification (Fig). In pts where stress testing
was indicated by the guidelines, the event rate was 7%. ESE provided further risk stratifi-
cation in this group (Fig).
Conclusions: 1) Compliance with preoperative stress testing guidelines in this popula-
tion is poor, resulting in extensive testing that provides no further risk stratification. 2)
Where stress testing is indicated by guidelines, ESE provides important prognostic infor-
mation.
1040-73 Financial Impact of Drug-Eluting Stents: The US 
Academic Experience
David S. Marks, Thomas A. Ratko, Karl A. Matuszewski, Michael J. Oinonen, Joseph P. 
Cummings, Medical College of Wisconsin, Milwaukee, WI, University HealthSystem 
Consortium, Oak Brook, IL
Background: Drug-eluting stents (DES) have recently been released in the United States
in limited quantity. These stents have changed the financial impact of coronary interven-
tion. The impact of DES in the initial US rollout has not been described.
Methods: The University HealthSystem Consortium (UHC) is an alliance of 87 academic
health centers in the US. The UHC clinical database was queried for DES implantation
compared to bare stent implantation for the second quarter (Q2) of 2003. This database
contains a comprehensive collection of procedure-specific data derived from discharge
abstract summaries and UB-92 data for all inpatients at participating centers.
Results: 11,866 procedures involving coronary stents from 74 institutions performed in
Q2 were analyzed, including 3,404 procedures using DES. Penetration of DES increased
monthly and reached 44% by June, 2003. Mean length of stay was lower for DES proce-
dures compared to bare stent procedures both with myocardial infarction (MI) (3.51±2.84
vs. 3.98±3.47 days, p<0.01) and without MI (1.99±2.29 vs.2.39±2.98, p<0.01). Overall
procedural costs increased for DES both with myocardial infarction ($18,150±9,900 vs.
$17,225±10,500) and without ($13,400±8,200 vs. $14,953±8,200). No difference existed
in payer status or clinical demographics between bare stents and DES.
Conclusion: The introduction of DES has increased costs to health care centers and the
technology has had rapid adoption despite limited supply. Yet, retrospective database
analysis suggests the cost of caring for patients with DES has risen by a quantity less
than the incremental price of a single stent; this may be explained, in part, by a
decreased LOS. No patient clinical or demographic criteria attesting to this savings has
been ascertained by a comprehensive clinical database. Further investigation is required
to understand the patient and physician characteristics that have determined DES utiliza-
tion and non-stent cost savings.
1040-74 Drug-Eluting Stent Use May Negatively Impact the 
Economic Health of a Hospital: A Single-Center Case 
Study
Richard E. Sinaiko, Mikele M. Bunce, Neal Eigler, Saibal Kar, Sepideh S. Farivar, Emma 
C. Wollschlager, Sinaiko Healthcare Consulting, Inc., Los Angeles, CA, Cedars-Sinai 
Health System, Los Angeles, CA
Background: Drug eluting stents (DES) are becoming the "gold standard" for treatment
of coronary artery disease due to decreased rates of restenosis. The economic implica-
tions of this costly technology may be greater than expected. This study was conducted
to forecast the financial impact of DES use on a major teaching hospital.
Methods: A case study hospital’s caseload, cost, and reimbursement data were used to
perform a sensitivity analysis using a financial impact model developed by Cordis, which
was run using two different sets of assumptions: (1) Cordis’ assumptions, and (2) case
study hospital’s assumptions. The case study hospital's assumptions were obtained by
surveying a group of the hospital’s interventional cardiologists.
Results: The results of this study (Figure 1) show that while Cordis’ assumptions show
less of an impact, under both Cordis’ and the case study’s assumptions, the case study
hospital will undergo a significant reduction in cardiovascular service line contribution
margin as a result of drug eluting stent use.
Conclusions: Hospitals have little control over the financial impact of DES due to
demand, liability, and guideline enforcement issues. To relieve the burden hospitals face
and to ensure the healthcare community has appropriate incentives to practice in a cost-
effective and patient centered way, Medicare should increase its reimbursement rates for
IMGs CMGs Adjusted Odds 
Ratio IMGs/CMGs 
(95% CI)
Medications within 90 days of hospital 
discharge, (%)
Aspirin 61.4 60.4 1.00 (0.94, 1.06)
Beta Blockers 53.8 56.4 1.01 (0.94, 1.07)
ACE inhibitors 51.3 52.0 1.04 (0.98, 1.11)
Statins 19.1 19.8 1.09 (1.01, 1.19)
Cardiac Procedures within 1 year of hospital 
discharge, (%)
Cardiac Catheterizations 31.0 32.6 1.06 (1.01, 1.18)
PCI 9.1 9.9 1.06 (1.00, 1.13)
CABG 9.6 10.3 1.00 (0.95, 1.06)
Category Admitted to 
Rev+ (n=18,817)
Admitted to 
Rev- (n=6527)
Transferred to 
Rev+ (n=3093)
USA pts in category (%) 22.1 20.4 41.3
Mean age (years) 65.5 66.7 62.6
+ve cardiac markers (init/pk; 
%)
63.0 57.7 76.5
Pts receiving PCI/CABG (%) 35.3/6.2 *2.6/0.5 50.5/10.9
Discharge-transfer to acute 
facility (%)
4.3 19.5 6.0
Total length of stay, days, 
mean (med) [95%CI]
8.9 (7.0) [8.8, 9.0] 8.5 (7.0) [8.3, 
8.7]
9.8 (7.0) [9.5, 
10.0]
Total index hospital costs, 
mean (med)[95%CI]
Europe
5595 
(4671)[5557, 
5633]
4267 
(3752)[4224, 
4310]
6732 (5428)[6628, 
6836]
US 6712 (5171) 
[6665, 6759]
3953 (3299) 
[3910, 3996]
8572 (7878) 
[8450, 8694]
Note all comparisons (1 vs 2) & (1 vs 3) P<0.001 except Wilcoxon for length of stay
*Some Rev- centers were linked to Rev+ centers as one combined trust
